This bill ends the liability shield for vaccine manufacturers by allowing individuals to sue directly in court or seek compensation through the existing program, while also removing time limits for program claims and excluding COVID-19 vaccines from countermeasure liability protections.
Paul Gosar
Representative
AZ-9
The End the Vaccine Carveout Act fundamentally changes vaccine injury compensation by allowing individuals to choose between filing a claim through the existing National Vaccine Injury Compensation Program or suing the manufacturer or administrator directly in court. This legislation removes the liability shield for vaccine makers and eliminates time limits for filing claims with the Program. Additionally, it specifically excludes COVID-19 vaccines from existing countermeasure liability protections.
The ‘End the Vaccine Carveout Act’ is a major shakeup to vaccine injury compensation, fundamentally changing the landscape for both manufacturers and individuals. This bill doesn't just tweak the existing system; it creates an entirely new path for seeking compensation. Essentially, it ends the near-exclusive protection vaccine manufacturers and administrators currently enjoy under the National Vaccine Injury Compensation Program (the Program).
Right now, if you suffer a vaccine injury, you must first file a claim through the federal Program, which is a no-fault administrative system. This bill changes that immediately. Starting on the day it becomes law, if you are injured by a vaccine, you get a choice: stick with the Program, or skip it entirely and sue the manufacturer or administrator directly in civil court (state or federal). The catch is that it's an either/or situation (Sec. 2). If you choose to sue and win a settlement or judgment, you can't go back and file a Program claim for that injury. Conversely, if you accept compensation from the Program, your right to sue in court for that same injury is gone. This is a huge deal because it exposes manufacturers to the full weight of traditional tort law, something they have largely been shielded from since the 1980s.
One of the most striking changes in this bill is the elimination of time limits for filing claims with the Program (Sec. 2). Currently, you have strict deadlines—usually 36 months from the first symptom of injury. Under this new law, you can file a petition with the Program at any time for a vaccine injury or death. This change is also retroactive, meaning it applies to past cases. For people with injuries that took years to manifest or who missed the old deadlines, this opens the door to compensation. However, it also means the Program could face a massive influx of very old claims, which might strain its resources and slow down the process for everyone.
Perhaps the most immediate and impactful change for the public health response is the specific exclusion of COVID-19 vaccines from ‘covered countermeasure’ protections (Sec. 2). During public health emergencies, certain countermeasures (like vaccines) are often granted broad liability shields to ensure rapid development and distribution. This bill explicitly removes that shield for COVID-19 vaccines. This means that if someone alleges injury from a COVID-19 vaccine, they can sue the manufacturer or administrator in civil court without the hurdles usually associated with emergency countermeasures. For manufacturers, this dramatically increases their financial risk concerning the most widely administered vaccines in recent history, potentially affecting future supply or pricing.
For the average person, this bill translates policy jargon into practical options. If you believe you were injured by a vaccine, you now have the power to choose your legal remedy. If you prefer the potentially faster, no-fault compensation of the federal Program, you can use it (and the new, unlimited filing window). If you feel the injury warrants a full civil lawsuit, allowing for discovery and potentially higher punitive damages, you can pursue that in court. This bill holds manufacturers more accountable by exposing them to the same legal risks faced by other product makers. The trade-off, however, is that increased liability costs for manufacturers could eventually trickle down into higher vaccine costs or, in extreme cases, reduced availability if companies decide the risk is too high.